You searched for "VEGF"

164 results found

Ranibizumab safety in pregnancy

Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...

Discussing treatment modalities for bilateral wet AMD

A 65-year-old lady with bilateral wet AMD and vision of 6/24 comes with an internet search about current therapies. How do you explain the various treatment modalities available? There are two NICE approved treatments for wet age-related macular degeneration (AMD)....

Akimba mice, a model of human diabetic retinopathy

Diabetic retinopathy (DR) is a major complication of diabetes and a growing problem as the systemic disease becomes more prevalent. DR develops insidiously from an asymptomatic form through to vascular damage that leads to oedema and breakdown of the blood-retinal...

MicroRNA inhibits corneal neovascularisation

MicroRNAs (miR) are small non-coding RNA that target mRNA for destruction. MiR target about 30% of the protein coding genes and fine tune their expression. MiR have been shown to be involved in several cellular processes including cell cycle, tissue...

Treatment efficacy of stage 4 ROP

This study aimed to determine the efficacy of combined vitrectomy and anti-VEGF injection for advanced stage 4 ROP with extensive neovascular proliferation (NF). The study included nine infants; six bilateral and three unilateral. Seven were female and the mean gestational...

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

Neovascular AMD: fresh recommendations underline standards of best practice

The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...

Management of diabetic macular oedema in vitrectomised eyes

Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

Do steroids prevent progression to proliferative diabetic retinopathy (PDR)?

There is continuing debate on the merits of pan-retinal photocoagulation (PRP) for severe pre-proliferative and proliferative DR versus the newer therapies that inhibit vascular endothelial growth factor (VEGF). This has been hotly debated [1] following the publication of findings from...

How does cataract surgery affect eyes with wet AMD?

In this retrospective cohort study the authors’ primary objective was to assess whether cataract surgery in eyes with wet age-related macular degeneration (AMD), triggered its progression. The surgical group comprised of 40 eyes versus 42 eyes in the non-surgical control...

2018 update on intravitreal injections

In this review article the authors have highlighted the standardised and structured approach to intravitreal injections (IVI) by examining the recent evidence-based literature. IVI is the most commonly performed procedure worldwide with low potential risk of endophthalmitis. IOP spikes are...